A new generation of brain stimulation technology is transforming how doctors treat Parkinson's disease by adjusting electrical impulses in real time rather than delivering the same constant stimulation all day long. Researchers at UCSF are now testing automated systems that could make this advanced therapy accessible to more patients and clinicians without specialized neurophysiology training.

What Is Adaptive Deep Brain Stimulation and Why Does It Matter?

Parkinson's disease affects approximately 1% of people over age 60 and causes progressive difficulty with movement, tremor, and rigidity. While dopamine-based medications work well early on, most patients eventually develop complications like motor fluctuations and involuntary movements called dyskinesias. Deep brain stimulation, or DBS, has long offered relief by surgically implanting electrodes in the brain that deliver electrical impulses through a pulse generator implanted in the chest.

The problem with traditional DBS is that it delivers constant stimulation with fixed parameters throughout the day, regardless of whether a patient is sitting quietly, walking, or experiencing symptom changes. This leaves many patients either under-stimulated during certain activities or over-stimulated at other times. Adaptive DBS, or aDBS, solves this by using real-time detection of neural signals to automatically adjust stimulation strength and other parameters based on what the patient's brain is actually doing at any given moment.

The U.S. Food and Drug Administration approved adaptive DBS for Parkinson's treatment in February 2025 through the Percept PC and RC devices made by Medtronic, marking a significant milestone in movement disorder care.

How Is UCSF Expanding Access to This Technology?

While adaptive DBS represents a major advance, widespread adoption has been limited by technical barriers. Setting up the system requires careful tuning of multiple control parameters through trial-and-error testing, a process that demands specialized knowledge of neurophysiology and feedback control systems. This expertise is not widely available, which has slowed the technology's rollout to clinics and hospitals across the country.

UCSF researchers are now conducting a clinical trial called "Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator," enrolling patients ages 25 to 75 with Parkinson's disease. The goal is to test an automated, data-driven pipeline that recommends optimal adaptive control parameters without requiring deep expertise in neurophysiology. If successful, this approach could dramatically simplify how clinicians implement adaptive DBS, making the therapy available to far more patients.

What Other Movement Disorders Are Being Targeted With DBS?

Beyond Parkinson's disease, UCSF is exploring deep brain stimulation for other movement disorders. One trial is testing cerebellar deep brain stimulation, which targets a different brain region called the cerebellum, to treat dyskinetic cerebral palsy in children and young adults ages 7 to 25. Researchers will use videotaped automated movement recognition and formal gait analysis to measure outcomes, along with neuroimaging to identify which patients respond best to the therapy.

Steps to Understanding Your DBS Options

• Medication Plateau: If you have Parkinson's disease and your dopamine medications are no longer controlling symptoms effectively, or if you are experiencing motor fluctuations and involuntary movements, discuss DBS eligibility with your neurologist.
• Adaptive vs. Conventional: Ask your care team whether adaptive DBS (which adjusts automatically) or conventional DBS (which delivers constant stimulation) might be appropriate for your situation, and whether clinical trials in your area are accepting participants.
• Trial Participation: If you meet eligibility criteria, inquire about enrolling in research studies that test new DBS optimization methods, which may offer access to cutting-edge technology while contributing to scientific knowledge.

The shift toward adaptive, personalized brain stimulation reflects a broader trend in neurology: moving away from one-size-fits-all treatments toward therapies that respond to each patient's unique brain activity patterns. For people with Parkinson's disease who have exhausted medication options, this technological leap offers a tangible path to better symptom control and improved quality of life.